Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 1 2Phase 1/2 1

Status

Unknown 3Active not recruiting 2

Sponsor Class

OTHER 5OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 5Lymphoid 2Gastrointestinal 1

Conditions

Breast Neoplasms 361Precursor Cell Lymphoblastic Leukemia-Lymphoma 328Lymphoma 297Leukemia 254Multiple Myeloma 246Leukemia, Myeloid, Acute 241Lymphoma, Non-Hodgkin 240Lymphoma, Large B-Cell, Diffuse 238Leukemia, Lymphocytic, Chronic, B-Cell 220Myelodysplastic Syndromes 184Lymphoma, Follicular 176Hodgkin Disease 165Lymphoma, Mantle-Cell 163Burkitt Lymphoma 160Lymphoma, B-Cell, Marginal Zone 117Recurrence 115Lymphoma, Large-Cell, Immunoblastic 95Leukemia, Myelogenous, Chronic, BCR-ABL Positive 82Myeloproliferative Disorders 81Melanoma 78Neoplasms, Plasma Cell 77Leukemia, Myeloid, Chronic-Phase 72Hematologic Neoplasms 72Leukemia, Myeloid, Accelerated Phase 71Leukemia, Myelomonocytic, Chronic 69Lymphoma, B-Cell 65Dendritic Cell Sarcoma, Interdigitating 64Triple Negative Breast Neoplasms 63Ovarian Neoplasms 61Congenital Abnormalities 59

Interventions

Cisplatin 104Radiotherapy, Intensity-Modulated 59Gemcitabine 53toripalimab 35Fluorouracil 30Docetaxel 30Capecitabine 28Radiotherapy 23Drug Therapy 20camrelizumab 19nimotuzumab 16nedaplatin 12Chemoradiotherapy 12sintilimab 11apatinib 11Induction Chemotherapy 11Immune Checkpoint Inhibitors 11spartalizumab 10endostar protein 8Paclitaxel 8Cetuximab 8tislelizumab 7pembrolizumab 7Endostatins 7Bevacizumab 7anlotinib 6Radiation 6Endoscopy 6fludarabine 5S 1 (combination) 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Nasopharyngeal Carcinoma × Cyclophosphamide × Clear all
NCT02287311 2026-03-23

MABEL

Baylor College of Medicine

Phase 1 Active not recruiting
38 enrolled 16 charts
Head & NeckLymphoid

Nasopharyngeal Carcinoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Smooth Muscle Tumor

NCT02065362 2026-01-29

TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

Baylor College of Medicine

Phase 1 Active not recruiting
14 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Camurati-Engelmann Syndrome

NCT05654077 2022-12-19

EBV CAR-T Cells for Nasopharyngeal Carcinoma

The Affiliated Hospital of Xuzhou Medical University

Phase EARLY_PHASE1 Unknown
24 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT05616468 2022-12-15

BGT007 Cell Treatment of Nasopharyngeal Carcinoma

The Affiliated Hospital of Xuzhou Medical University

Phase EARLY_PHASE1 Unknown
23 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT03044743 2017-05-02

PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 1/2 Unknown
20 enrolled
GastrointestinalHead & NeckLymphoid

Nasopharyngeal Carcinoma, Hodgkin Disease, Stomach Neoplasms, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡